$CRSP

CRISPR Therapeutics AG

CRISPR Therapeutics develops CRISPR-based gene-editing medicines for serious diseases. Its portfolio spans hemoglobinopathies, in vivo editing, CAR T cell therapies and regenerative medicine. Its most advanced product, CASGEVY, is an ex vivo cell therapy approved for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia and is developed and commercialized with Vertex. Other programs include in vivo gene-editing candidates targeting liver diseases, siRNA programs developed with Sirius Therapeutics, gene-edited CAR T candidates for autoimmune diseases and cancer, and a beta cell replacement candidate for Type 1 diabetes. The company works with partners to develop and commercialize therapies, including Vertex for CASGEVY and Sirius for siRNA products. It also develops gene-editing and delivery technologies, including its proprietary SyNTase platform. CRISPR Therapeutics is headquartered in Zug.

2
1
1
—
$2.4M
Kulkarni Samarth
0%
See all $CRSP insider activity →
Med

CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build

CRISPR Therapeutics reported progress in clinical trials for zugo-cel and CTX611, with positive early responses and completed enrollment, respectively. CASGEVY demand reached near $100M revenue run rate. The company expects key data readouts by year-end and in 2024, including CTX611 Phase II results and early data for CTX340 and alpha-1 antitrypsin programs.

‘We just witnessed a first’: Gene-editing therapy lowers triglycerides in early study

CRISPR Therapeutics' gene-editing therapy CTX310 reduced triglycerides by 62.8% at 30 days in a phase 1b study of 10 patients with severe hypertriglyceridemia. No serious adverse events were reported. The therapy is not yet approved for commercial use in the U.S. According to researchers, the median triglyceride change ranged from -299.4 mg/dL to -1,971.6 mg/dL.

CRSP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CRSP (CRISPR Therapeutics AG). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.

Recent CRSP coverage spans financial news and technology.

In the last 30 days, CRSP insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.4M). The most active reporter was Kulkarni Samarth, Chief Executive Officer, with 1 filing.

What's driving CRSP

AlphAI scores every news story that mentions CRSP with an AI model for sentiment and relevance, and aggregates insider trades from CRISPR Therapeutics AG's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CRSP

Score
$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch

Five mid-cap biotechs are highlighted with upcoming catalysts. Cytokinetics (CYTK) awaits an FDA decision on Nov 14. Arrowhead (ARWR) reports earnings on Nov 12, while Ionis (IONS) saw a post-earnings sell-off. Crispr (CRSP) and Viking (VKTX) have undated catalysts. CYTK's Q3 revenue was $47.6M, beating estimates. ARWR's consensus EPS is -1.55, and IONS beat EPS and revenue estimates. CRSP showed Phase 1b data, and VKTX's next earnings are tentatively Feb 10, 2027.

Related tickers